Tonix Acquires Two FDA-Approved, Marketed Migraine Products From Upsher-Smith Laboratories

Tonix Pharmaceuticals Holding Corp. TNXP acquired Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg from Upsher-Smith Laboratories for about $25 million.

The products are FDA-approved, marketed, and indicated for treating acute migraine in adults.

The strategic acquisition helps build Tonix's commercial capabilities and infrastructure ahead of the potential launch of TNX-102 SL for managing Fibromyalgia.

"The acquisition of these two products represents an important step in the evolution of Tonix into a fully integrated biopharmaceutical company and builds on our expertise in central nervous systems disorders," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. 

Also Read: Tonix Pharmaceuticals Fast Forwards Its Fibromyalgia, Migraine Studies

The company said that Zembrace SymTouch is the only actively promoted brand of sumatriptan autoinjector in the U.S. (other sumatriptan autoinjector products on the market are Imitrex and generics to Imitrex). 

Tosymra currently has patent protection until 2031.

These products collectively generated product sales of approximately $23 million for the entire year 2022.

"Migraine headaches and breakthrough migraine headaches remain a significant burden, and we believe both Zembrace SymTouch and Tosymra are well-suited to address the unmet needs of patients currently using traditional or emerging oral acute migraine medications, particularly for rapid-onset treatment," said James Hunter, Executive Vice President of Commercial Operations at Tonix.

Price Action: TNXP shares are trading higher by 2.04% to $1.6123 on the last check Monday.